Angiogenesis: A therapeutic target in arthritis

Current Opinion in Investigational Drugs

Volumn 2, Issue 8, 2001, Pages 1054-1063

  Walsh, D A ^a   Haywood, L ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Angiogenesis; Ankylosing spondylitis; Inflammation; Ossification; Osteoarthritis; Psoriatic arthritis; Rheumatoid arthritis; Spondylosis

Indexed keywords

ADHESION MOLECULE INHIBITOR; ANGIOGENESIS FACTOR INHIBITOR DERIVATIVE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; ANGIOSTATIN; ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; COMBRETASTATIN; DEXTRIN; ENDOGLIN; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOCOUMARIN DERIVATIVE; LEUKEMIA INHIBITORY FACTOR; LIGAND; MANNOSAMINE; MICROTUBULE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN TYROSINE KINASE INHIBITOR; SIALIC ACID DERIVATIVE; SURAMIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTHROPATHY; ARTICULAR CARTILAGE; BONE REMODELING; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; GROWTH, DEVELOPMENT AND AGING DISORDERS; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INHIBITION KINETICS; MOLECULAR DYNAMICS; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; PHARMACEUTICAL ENGINEERING; RECEPTOR DOWN REGULATION; REPRODUCTIVE TOXICITY; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; SYNOVITIS; TREATMENT PLANNING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ARTHRITIS; CLINICAL TRIALS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034887186     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. The role of angiogenesis in rheumatoid arthritis: Recent developments
3. Angiogenesis and arthritis
4. Innervation and neurokinin receptors during angiogenesis in the rat sponge granuloma
5. Cyclic angiogenesis and blood vessel regression in the ovary: Blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion
6. Focally regulated endothelial proliferation and cell death in human synovium
7. Vascular turnover during carrageenan synovitis in the rat
8. Oncoprotein expression in human synovial tissue: An immunohistochemical study of different types of arthritis
9. Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis
10. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues
11. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium
12. A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium
13. Aberrant vascularity and von Willebrand factor distribution in inflamed synovial membrane
14. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis
15. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging
16. Degenerative disk vascularization on MRI: Correlation with clinical and histopathologic findings
17. Angiogenesis and angiogenic growth factors in the synovium in early rheumatoid arthritis
18. The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage
19. Endothelial cell stimulating angiogenesis factor - A new biological marker for disease activity in ankylosing spondylitis?
20. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases
21. Role of macrophages in angiogenesis-dependent diseases
22. Quantitation of histamine-induced angiogenesis in the chick chorioallantoic membrane: Mode of action of histamine is indirect
23. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
24. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
25. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
26. Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2
27. Distributional changes in substance P nociceptive fiber patterns in naturally osteoarthritic articulations
28. Definition of two angiogenic pathways by distinct alpha v integrins
29. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1
30. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
31. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
32. Thymidine phosphorylase is angiogenic and promotes tumor growth
33. Bradykinin as a growth factor
34. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells
35. Calcitonin gene-related peptide stimulates proliferation of human endothelial cells
36. Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma
37. AT1 receptor characteristics of angiotensin analogue binding in human synovium
38. Vasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants
39. PGE2 and angiogenesis
40. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P
41. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases
42. Histamine levels in human synovial fluid
43. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis
44. Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor
45. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease
46. Defective angiogenesis in mice lacking endoglin
47. Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: Possible interactions in the pathogenesis of the disease
48. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
49. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis
50. Transforming growth factor-alpha: A more potent angiogenic mediator than epidermal growth factor
51. Human epidermal growth factor for the stratification of synovial lining layer and neovascularisation in rheumatoid arthritis
52. Interleukin-1 induces corneal neovascularisation
53. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: Prolonged production of IL-1 alpha
54. Interleukin-8 as a macrophage-derived mediator of angiogenesis
55. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells
56. Expression of basic fibroblast growth factor and angiogenin in arthritis
57. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
58. Enhanced expression of transforming growth factor-beta and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis
59. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha
60. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis
61. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium
62. Angiogenic factor from synovial fluid resembling that from tumours
63. Thrombospondin as a regulator of angiogenesis
64. Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues
65. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses
66. Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis
67. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro
68. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis
69. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2)
70. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium
71. Expression of stromelysin 3 and tissue inhibitors of matrix metallo-proteinases, TIMP-1 and TIMP-2, in rheumatoid arthritis
72. A role of transforming growth factor-beta 1 in the control of corneal neovascularization
73. Dual role of tumor necrosis factor-alpha in angiogenesis
74. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
75. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
76. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis
77. Angiogenesis induced by degradation products of hyaluronic acid
78. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity
79. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
80. 1 or interleukin-1 receptor antagonists
81. Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis
82. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis
83. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis
84. Angiogenesis inhibition suppresses collagen arthritis
85. Decreased v angiogenesis and arthritic disease in rabbits treated with αv β3 antagonist
86. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis
87. Modulation of T lymphocyte function by the angiogenesis inhibitor AGM-1470
88. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis
89. Disease-modifying activity of SB 273005, an orally active, nonpeptide αvβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis
90. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol
91. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
92. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis
93. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis
94. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine
95. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate
96. Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization?
97. Inhibition of neovascularization in vivo by gold compounds
98. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
99. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
100. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
101. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
102. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins
103. Aberrant renal vascular morphology and renin expression in mutant mice lacking angiotensin-converting enzyme
104. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P
105. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene
106. Angiotensinogen-deficient mice with hypotension
107. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes
108. Targeted disruption of the mouse B2 bradykinin receptor in embryonic stem cells
109. Physiological roles of matrix metalloproteinases: Implications for tumor growth and metastasis